# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN
- Date: 2026-10-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Cycle 2 review on pembrolizumab. **S**

## History of present illness

Mr. Brynner returns three weeks after his first pembrolizumab infusion, for cycle 2. He felt a little more tired for two days after the infusion and has otherwise felt well. He has had no diarrhea, abdominal pain, new cough or breathlessness, rash or itching, headache, dizziness, thirst, or yellowing. He saw the palliative care team two weeks ago and found the conversation about his goals and his worries useful; he is sleeping better. The injection medialization of his left vocal fold a week ago made his voice louder and less breathy, and he has begun light rehearsal with the voice therapist's exercises. He wants to rejoin the tour for a few performances a week next month. He has had no bone pain and has not smoked. His first zoledronic acid dose is today, with the pembrolizumab. **S**

| Element | Detail |
|---|---|
| Tolerance of cycle 1 | Two days of extra tiredness; no immune-related symptoms |
| Palliative care | First visit two weeks ago |
| Voice | Louder after injection medialization a week ago; light rehearsal begun |
| Work | Plans a graded return to the tour next month |
| Bone symptoms | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Two days of extra tiredness after the infusion; no fever |
| Respiratory | Positive | Occasional morning dry cough, unchanged; no new breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or blood in the stool |
| Integumentary | Negative | No rash or itching |
| Endocrine | Negative | No headache, dizziness, heat or cold intolerance, or thirst |
| Psychiatric | Negative | Mood steady; sleeping better; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks **S**
- Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases **S**
- Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 72.2 kg; BMI 22.8 kg/m². All vital signs are synthetic.

TSH: 2.4 mIU/L; Free T4: 1.1 ng/dL; ALT: 30 U/L; AST: 27 U/L; Total bilirubin: 0.7 mg/dL; Creatinine: 0.9 mg/dL; eGFR: 92 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Calcium: 9.4 mg/dL; Hemoglobin: 13.5 g/dL; White cell count: 7.2 10*3/uL; Platelets: 270 10*3/uL; ESAS total symptom distress score: 12; PHQ-9: 4. All results are synthetic.

## Change since baseline

- ALT: 24 U/L at baseline, 30 U/L at this visit **S**
- AST: 22 U/L at baseline, 27 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- Creatinine: 0.9 mg/dL at baseline, 0.9 mg/dL at this visit **S**
- eGFR: 92 mL/min/1.73 m² at baseline, 92 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 104 mg/dL (high) at this visit **S**
- Calcium: 9.6 mg/dL at baseline, 9.4 mg/dL at this visit **S**
- Hemoglobin: 13.8 g/dL at baseline, 13.5 g/dL at this visit **S**
- White cell count: 7.9 10*3/uL at baseline, 7.2 10*3/uL at this visit **S**
- Platelets: 290 10*3/uL at baseline, 270 10*3/uL at this visit **S**
- PHQ-9: 5 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 72.2 kg |
| Voice | Louder and less breathy; longer phonation time |
| Lungs | Slightly reduced breath sounds at the left apex; no crackles |
| Skin | No rash |
| Mouth | Good dentition; no exposed bone |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the lung, stage IVB, on pembrolizumab** (C34.12). Cycle 1 tolerated well. TSH 2.4 and free T4 1.1, liver tests, creatinine, and blood count normal; glucose 104 mg/dL on a mid-morning, non-fasting sample is not a concern. No immune-related adverse event. ESAS 12, down from 18; PHQ-9 4. **S**
   - Pembrolizumab cycle 2 today.
   - Laboratory panel before cycle 3; response CT about nine weeks after starting.
   - Once the first response scan is reviewed, consider pembrolizumab 400 mg every 6 weeks to fit the tour.
2. **Bone metastases** (C79.51). No pain; calcium 9.4 and eGFR 92; dental examination done. **S**
   - Zoledronic acid 4 mg today, then every 12 weeks.
   - Vitamin D3 1000 units daily and calcium from food.
   - Acetaminophen for aches after the first dose if needed.
3. **Left vocal fold paralysis, after injection medialization** (J38.01). Voice much improved. **S**
   - Continue voice therapy; graded return to performing as he chooses, with rest days between performances at first.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Completed today | TSH 2.4, free T4 1.1, ALT 30, AST 27, bilirubin 0.7, glucose 104 (non-fasting); no immune-related adverse event |
| Laboratory | Morning cortisol | At baseline and as indicated by symptoms (ASCO); the CMID lists it before each infusion | Not indicated | Baseline 14.2 was normal, and he has no fatigue, dizziness, low blood pressure, or low sodium suggesting adrenal or pituitary injury; repeated if symptoms appear |
| Laboratory | Blood count, kidney function, and calcium before treatment and before zoledronic acid | Before each cycle and each zoledronic acid dose | Completed today | Hemoglobin 13.5, white cells 7.2, platelets 270, creatinine 0.9 (eGFR 92), calcium 9.4 |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Due | First response CT in about six weeks, nine weeks after starting |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Occasional morning cough, unchanged; no new breathlessness to suggest pneumonitis |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Completed today | ESAS total 12, down from 18; distress thermometer 3 of 10; completed at check-in |
| Survey | Depression and anxiety screening | At least yearly; more often during active treatment | Completed today | PHQ-9 4, item 9 scored 0 |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Two days of extra tiredness after cycle 1, then back to his usual |
| Examination | Weight and dietary review | Each follow-up | Completed today | 72.2 kg, stable |
| Medication safety | Dental evaluation on a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Up to date | Baseline examination three weeks ago; routine dental care every six months |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Completed today | First visit two weeks ago, two weeks after diagnosis; follow-up next month |
| Self-management | Voice and work support | As needed | Completed today | Injection medialization a week ago; voice therapy continues; graded return to the tour planned |
| Medication safety | Immunizations per ACIP | Yearly review | Due | Influenza, PCV20, and zoster at the preventive visit in two weeks |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | No platinum or taxane |

## Goal progress

- Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation. Outcome by 2026-09-22: Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed. **S**
- First palliative care visit within eight weeks of diagnosis. Outcome by 2026-10-13: Seen by the palliative care team two weeks after diagnosis. **S**
- A voice strong enough for rehearsal by the second cycle. Outcome by 2026-10-13: Louder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy. **S**
- No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit. Outcome by 2026-10-13: Panels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction. **S**
- Zoledronic acid started only after a dental examination and normal calcium and kidney function. Outcome by 2026-10-13: Dental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2. **S**

## Medication changes

- Started: Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases **S**
- Started: Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)
- NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026), National Comprehensive Cancer Network

## Follow-up

- Pembrolizumab cycle 2 and zoledronic acid today. Preventive visit in two weeks. Cycle 3 in three weeks with the laboratory panel. Response CT about nine weeks after starting. **S**
- Next scheduled visit 2026-10-27: periodic adult preventive visit. **S**
